diet Short Term Fasting Cancer Research Results

dietSTF, diet Short Term Fasting: Click to Expand ⟱
Features:
Short-term fasting (STF) 48 to 72 h before chemotherapy appears to be more effective than intermittent fasting. Preliminary data show that STF is safe but challenging in cancer patients receiving chemotherapy.

Short-Term Fasting (STF; ~24–72 h water / very low calorie fast) Cancer vs Normal Cell Effects
Rank Pathway / Axis Cancer Cells Normal Cells Label Primary Interpretation Notes
1 Insulin / IGF-1 signaling ↓ IGF-1 survival signaling (stress) ↓ IGF-1 with adaptive protection Driver Differential stress resistance (DSR) Cancer cells fail to adapt to acute IGF-1 withdrawal; normal cells enter protective mode
2 AMPK → mTOR nutrient sensing ↑ AMPK; ↓ mTOR (growth crisis) ↑ AMPK; ↓ mTOR (protective quiescence) Driver Catabolic enforcement Rapid mTOR suppression removes anabolic support from tumors
3 Autophagy (ATG program) ↑ autophagy → metabolic exhaustion ↑ autophagy → cytoprotection Driver Catabolic stress vs survival recycling Autophagy is protective in normal cells but destabilizing in cancer cells
4 Mitochondrial metabolism / flexibility ↓ metabolic flexibility; ↓ ATP resilience ↑ mitochondrial efficiency Secondary Energy crisis vs optimization Tumors struggle to switch fuels; normal cells adapt
5 Reactive oxygen species (ROS) ↑ ROS (secondary to energy stress) ↓ ROS Secondary Metabolic redox divergence ROS increase is indirect, arising from metabolic collapse
6 NRF2 antioxidant response ↔ or insufficient activation ↑ NRF2 (protective) Adaptive Stress buffering in normal cells Normal cells activate antioxidant defenses; tumors often cannot
7 Cell cycle / proliferation ↓ proliferation / ↑ arrest ↓ proliferation (protective quiescence) Phenotypic Growth suppression Cell-cycle slowdown reflects upstream nutrient deprivation
8 Therapy sensitivity (chemo / RT) ↑ sensitivity ↓ toxicity Phenotypic Differential stress sensitization STF selectively sensitizes tumors while protecting normal tissue

Fasting Type vs Effectiveness
Fasting Type Definition Primary Metabolic / Signaling Effects Cancer-Relevant Mechanisms Evidence Base Relative Effectiveness*
Caloric Restriction (CR) Chronic daily reduction in total caloric intake (typically 20–40%) without malnutrition. ↓ insulin, ↓ IGF-1, ↓ mTOR, ↑ AMPK, ↑ autophagy Reduces growth signaling; improves metabolic milieu; may slow tumor initiation/growth in models. Extensive animal data; observational human data. Moderate–High
Caloric Restriction Mimetic (CRM) Non-fasting interventions that mimic CR signaling without major calorie reduction. ↓ mTOR, ↑ AMPK, ↑ autophagy; altered acetyl-CoA/epigenetic tone (context-dependent) Replicates key CR pathways while preserving nutrition; potential synergy with therapy (context-specific). Strong mechanistic + preclinical; growing human data. Moderate–High
Intermittent Fasting (IF) Regular cycles of fasting and feeding (e.g., 16:8, 18:6, 20:4). Periodic ↓ insulin/IGF-1; ↑ fat oxidation; mild ketosis (variable) Metabolic stress on tumor cells; improved insulin sensitivity; may modulate inflammation. Good animal data; emerging human data. Moderate
Alternate-Day Fasting (ADF) Alternating 24 h fasting with 24 h ad libitum feeding. Strong oscillations in insulin/glucose/ketones; improved metabolic switching Enhanced metabolic flexibility; may promote normal-cell stress resistance. Animal data strong; limited oncology-specific human data. Moderate–High
Short-Term Fasting (STF) Complete or near-complete fasting for ~24–72 h (often around therapy). Sharp ↓ IGF-1; ↓ glucose; ↑ ketones; ↑ autophagy Differential stress resistance (normal-cell protection) and potential tumor sensitization (context-specific). Strong preclinical; small human trials. High
Fasting-Mimicking Diet (FMD) Low-calorie, low-protein, low-sugar diet for 3–5 days designed to simulate fasting. ↓ IGF-1; ↓ mTOR; ↑ autophagy; partial ketosis Similar benefits to STF with improved tolerability; may enhance therapy response in some contexts. Strong animal; increasing human interventional data. High
Protein Restriction (PR) Reduction in total protein or specific amino acids (e.g., methionine restriction). ↓ IGF-1; ↓ mTORC1; altered amino-acid sensing Targets amino-acid dependencies and growth signaling; may synergize with selected therapies. Strong mechanistic; animal + early human data. Moderate–High
Ketogenic / Very-Low-Carb Diet Diet inducing sustained ketosis without fasting (variable protein content). ↓ glucose; ↓ insulin; ↑ ketones May constrain glycolysis-dependent tumors; effects are heterogeneous by cancer type and context. Mixed animal data; heterogeneous human data. Low–Moderate
Time-Restricted Feeding (TRF) Fixed daily eating window (typically 6–12 h), emphasizing circadian alignment. Circadian stabilization; modest ↓ insulin exposure; partial metabolic switching Improves metabolic control; limited deep autophagy unless fasting is long (≥18–20 h). Early-stage; indirect oncology evidence. Low–Moderate
Water-Only Prolonged Fasting Extended complete fasting (>72 h). Deep ketosis; strong autophagy; high physiological stress Potentially strong tumor stress but higher risk and limited controlled oncology study. Limited / heterogeneous; safety considerations significant. Uncertain / Not Rated 
Notes on Effectiveness Ratings
-High: Consistent preclinical efficacy + mechanistic clarity + early human interventional support
-Moderate–High: Strong biology with partial human validation
-Moderate: Solid rationale but limited oncology-specific human data
-Low–Moderate: Indirect or context-dependent effects
-Uncertain: Insufficient or high-risk evidence base
TRF Pattern Feeding Window Fasting Duration Metabolic Depth Cancer-Relevant Effects
14:10 TRF 10 h eating / 14 h fast 14 h Mild Improves insulin sensitivity; typically minimal autophagy.
16:8 TRF 8 h eating / 16 h fast 16 h Mild–Moderate Reduces daily insulin/IGF-1 exposure; partial metabolic switching.
18:6 TRF 6 h eating / 18 h fast 18 h Moderate Greater fat oxidation; autophagy initiation more likely (variable).
20:4 TRF 4 h eating / 20 h fast 20 h Moderate–High Lower insulin for longer; early ketosis in some individuals; more “fasting-like.”
22:2 TRF 2 h eating / 22 h fast 22 h High (borderline IF) Strong circadian + metabolic stress; limited tolerability for many. 
Circadian Timing (Critical for Cancer Relevance)
Early TRF (eTRF)
-Feeding window: ~07:00–15:00 or 08:00–16:00
-Superior reductions in insulin, glucose AUC, and IGF-1 signaling
-Aligns with PER/CRY, BMAL1, CLOCK oscillations
-More favorable for cancer-relevant metabolic control
Late TRF
-Feeding window: ~12:00–20:00 or later
-Weaker insulin and IGF-1 suppression
-Circadian misalignment may blunt benefits


Scientific Papers found: Click to Expand⟱
1626- dietSTF,  dietFMD,    When less may be more: calorie restriction and response to cancer therapy
- Review, Var, NA
"highlight2" >CRM↑, "highlight2" >ChemoSen↑, "highlight2" >RadioS↑, "highlight2" >eff↑, "highlight2" >eff↑, "highlight2" >IGF-1↓, "highlight2" >TumCG↓, "highlight2" >AMPK↑, "highlight2" >eff↑, "highlight2" >ChemoSen↑, "highlight2" >RadioS↑, "highlight2" >ROS↑, "highlight2" >DNAdam↑, "highlight2" >eff↑, "highlight2" >HO-1↓,
3707- dietSTF,    Intermittent fasting protects against the deterioration of cognitive function, energy metabolism and dyslipidemia in Alzheimer’s disease-induced estrogen deficient rats
- in-vivo, AD, NA
"highlight2" >*memory↑, "highlight2" >*Aβ↓, "highlight2" >*AST↓, "highlight2" >*ALAT↓,
3708- dietSTF,    Fasting as a Therapy in Neurological Disease
"highlight2" >*PGC-1α↑, "highlight2" >*AMPK↑, "highlight2" >*adiP↑, "highlight2" >*glucose↓, "highlight2" >*Insulin↓, "highlight2" >*mTOR↓, "highlight2" >*IL6↓, "highlight2" >*TNF-α↓, "highlight2" >*cognitive↑, "highlight2" >*Inflam↓, "highlight2" >*eff↑, "highlight2" >*neuroP↑, "highlight2" >ChemoSen↑, "highlight2" >eff↓, "highlight2" >chemoP↑, "highlight2" >*eff↑,
3709- dietSTF,    Intermittent Fasting Protects against Alzheimer’s Disease Possible through Restoring Aquaporin-4 Polarity
- in-vitro, AD, NA
"highlight2" >*cognitive↑, "highlight2" >*Aβ↓, "highlight2" >*AQPs↓, "highlight2" >*HDAC3↓,
4159- dietSTF,  2DG,  CRMs,    Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms
- Review, AD, NA
"highlight2" >*BDNF↑, "highlight2" >*HSPs↑, "highlight2" >*eff↑,
4180- dietSTF,    Brain-derived neurotrophic factor, but not body weight, correlated with a reduction in depression scale scores in men with metabolic syndrome: a prospective weight-reduction study
- Human, Obesity, NA
"highlight2" >*BDNF↑,
5065- dietSTF,  dietFMD,    Nutrition, GH/IGF-I Signaling, and Cancer
- Review, Var, NA
"highlight2" >GH↓, "highlight2" >IGF-1↓, "highlight2" >glucose↓, "highlight2" >IGFBP1↑, "highlight2" >OS↑, "highlight2" >Imm↑, "highlight2" >neuroP↑, "highlight2" >BMD↑, "highlight2" >Dose↝, "highlight2" >Risk↓, "highlight2" >other↑, "highlight2" >TumCP↓,
5066- dietSTF,    Intermittent and Periodic Fasting, Hormones, and Cancer Prevention
- Review, Var, NA
"highlight2" >IGF-1↓, "highlight2" >OS↑, "highlight2" >AntiAge↑, "highlight2" >glucose↓, "highlight2" >Insulin↓,
5068- dietSTF,    mTOR-autophagy axis regulation by intermittent fasting promotes skeletal muscle growth and differentiation
- in-vivo, Nor, NA
"highlight2" >*glucose↓, "highlight2" >ROS↑, "highlight2" >LC3B↑, "highlight2" >p62↓, "highlight2" >p‑mTOR↓, "highlight2" >p‑AMPK↑,
5069- dietSTF,    The Role of Intermittent Fasting in the Activation of Autophagy Processes in the Context of Cancer Diseases
- Review, Var, NA
"highlight2" >Risk↓, "highlight2" >ChemoSen↑, "highlight2" >RadioS↑, "highlight2" >*Dose↝, "highlight2" >*Dose↝, "highlight2" >*Dose↝, "highlight2" >*LDL↓, "highlight2" >*CRP↓, "highlight2" >*TNF-α↓, "highlight2" >TumAuto↓, "highlight2" >GLUT1↓, "highlight2" >GLUT2↓, "highlight2" >glucose↓, "highlight2" >IGF-1↓, "highlight2" >Insulin↓, "highlight2" >mTOR↓, "highlight2" >mTORC1↓, "highlight2" >AMPK↑, "highlight2" >Warburg↓, "highlight2" >OXPHOS↑, "highlight2" >ROS↑, "highlight2" >DNAdam↑, "highlight2" >JAK1↓, "highlight2" >STAT↓, "highlight2" >TumCP↓, "highlight2" >QoL↑,
5070- dietSTF,    A review of fasting effects on the response of cancer to chemotherapy
- Review, Var, NA
"highlight2" >chemoP↑, "highlight2" >ChemoSen↑, "highlight2" >*DNArepair↑, "highlight2" >*Apoptosis↓, "highlight2" >*CD8+↑, "highlight2" >UPR↑, "highlight2" >eff↝, "highlight2" >TumAuto↑,
5071- dietSTF,    Unraveling the impact of intermittent fasting in cancer prevention, mitigation, and treatment: A narrative review
- Review, Var, NA - Review, AD, NA
"highlight2" >Risk↓, "highlight2" >TumCMig↓, "highlight2" >IGF-1↓, "highlight2" >TumAuto↑, "highlight2" >Inflam↓, "highlight2" >ChemoSen↑, "highlight2" >Apoptosis↑, "highlight2" >chemoP↑, "highlight2" >*glucose↓, "highlight2" >*AntiDiabetic↑, "highlight2" >*cardioP↑, "highlight2" >*LDL↓, "highlight2" >*BP↓, "highlight2" >*neuroP↑, "highlight2" >*cognitive↑, "highlight2" >*memory↑, "highlight2" >*OS↑, "highlight2" >*QoL↑, "highlight2" >Imm↑, "highlight2" >TumCG↓, "highlight2" >ChemoSideEff↓, "highlight2" >QoL↑,
597- VitC,  dietSTF,  GlucDep,    The Result of Vitamin C Treatment of Patients with Cancer: Conditions Influencing the Effectiveness
"highlight2" >other↝, "highlight2" >H2O2↑, "highlight2" >ROS↑,

Showing Research Papers: 1 to 13 of 13

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 13

Pathway results for Effect on Normal Cells:


Mitochondria & Bioenergetics ⓘ

Insulin↓, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis ⓘ

adiP↑, 1,   ALAT↓, 1,   AMPK↑, 1,   glucose↓, 3,   LDL↓, 2,  

Cell Death ⓘ

Apoptosis↓, 1,  

Protein Folding & ER Stress ⓘ

HSPs↑, 1,  

DNA Damage & Repair ⓘ

DNArepair↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

HDAC3↓, 1,   mTOR↓, 1,  

Barriers & Transport ⓘ

AQPs↓, 1,  

Immune & Inflammatory Signaling ⓘ

CRP↓, 1,   IL6↓, 1,   Inflam↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 2,  

Protein Aggregation ⓘ

Aβ↓, 2,  

Drug Metabolism & Resistance ⓘ

Dose↝, 3,   eff↑, 3,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   BP↓, 1,   CRP↓, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

AntiDiabetic↑, 1,   cardioP↑, 1,   cognitive↑, 3,   memory↑, 2,   neuroP↑, 2,   OS↑, 1,   QoL↑, 1,  

Infection & Microbiome ⓘ

CD8+↑, 1,  
Total Targets: 34

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:226  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page